drugset

drugset / Trial / NCT04569916

Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors

NCT04569916 ↗

Phase 2 Unknown 30 enrolled The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

NaSingle-groupOpen-labelTreatment

Summary

An exploratory study to evaluate for the treatment of advanced solid tumors that failed standard treatments.

Timeline

Start: 2020-09
Primary completion: 2023-02
Completion: 2023-05

Publications

Shen J, Yan J, Du J, Li X, Wei J, Liu Q, Yong H, Wang X, Chang X, Ding Z, Sun W, Liu C, Zhu S, Guo J, Li H, Liu Y, Zhang W, Liu Z, Li R, Liu B. Multicenter, single-arm, phase II study (CAP) of radiotherapy plus liposomal irinotecan followed by camrelizumab and anti-angiogenic treatment in advanced solid tumors. Front Immunol. 2023 Mar 28;14:1133689. doi: 10.3389/fimmu.2023.1133689. eCollection 2023.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Camrelizumab	Monoclonal antibody	200 mg	Intravenous
Subject	Irinotecan	Small molecule	80 mg/m2	Intravenous
Subject	Rivoceranib	Small molecule	—	—

Indications